VITASPRING BIOMEDICAL CO. LTD. (VSBC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 01-31. Amounts in USD.

Revenue TTM

-2.5M 0 2.5M 5M 7.5M Q2 '22: 2.2M Q3 '22: 2.4M Q4 '22: 5.6M Q1 '23: 6.6M Q2 '23: 5.2M Q3 '23: 5M Q4 '23: 0 Q1 '24: -1.5M Q2 '24: -1.5M Q3 '24: -1.5M Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q4 '26: 0 Q1 '27: 0 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '19: 15.9K Q2 '19: 15.6K Q3 '19: 12.6K Q4 '19: 13.7K Q1 '20: 10.3K Q2 '20: 12.2K Q3 '20: 15.7K Q4 '21: 112.2K Q1 '22: 352K Q2 '22: 693.2K Q3 '22: 713.2K Q4 '22: 2.1M Q1 '23: 2.4M Q2 '23: 2.1M Q3 '23: 2M Q4 '23: -3.3M Q1 '24: -3.9M Q2 '24: -3.9M Q3 '24: -3.9M Q4 '24: 0 Q2 '19 Q1 '20 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Income TTM

-6M -4M -2M 0 2M 4M 6M Q2 '21: -86.8K Q3 '21: -169K Q4 '22: 2M Q1 '23: 2.2M Q2 '23: 1.7M Q3 '23: 1.4M Q4 '23: -4.2M Q1 '24: -4.8M Q2 '24: -5M Q3 '24: -5.1M Q4 '24: -1.1M Q1 '25: -1M Q2 '25: -895.9K Q3 '25: -778.8K Q4 '25: -679.9K Q1 '26: -532.2K Q2 '26: -412.6K Q3 '26: -430.4K Q4 '26: -385.4K Q1 '27: -392.1K Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income TTM

-6M -4M -2M 0 2M 4M 6M Q2 '22: 518.5K Q3 '22: 1.2M Q4 '22: 1.3M Q1 '23: 1.4M Q2 '23: 1.5M Q3 '23: 581.2K Q4 '23: -4.2M Q1 '24: -4.7M Q2 '24: -5M Q3 '24: -5.1M Q4 '24: -1.1M Q1 '25: -1M Q2 '25: -895.9K Q3 '25: -857.2K Q4 '25: -774.9K Q1 '26: -638.6K Q2 '26: -530.8K Q3 '26: -477K Q4 '26: -415.4K Q1 '27: -410.7K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue TTM

0 1.5M 3M 4.5M Q4 '20: 16.5K Q1 '21: 15.6K Q2 '21: 12K Q3 '21: 8.5K Q4 '21: 136K Q1 '22: 430K Q2 '22: 1.5M Q3 '22: 1.7M Q4 '22: 3.5M Q1 '23: 4.2M Q2 '23: 3.1M Q3 '23: 2.9M Q4 '23: 3.3M Q1 '24: 2.4M Q2 '24: 2.4M Q3 '24: 2.4M Q4 '24: 0 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Cash Flow TTM

-750K -500K -250K 0 250K 500K 750K Q2 '22: -661.3K Q3 '22: -284.5K Q4 '22: -269.6K Q1 '23: -656.6K Q2 '23: 263.2K Q3 '23: -111.1K Q4 '23: -77.6K Q1 '24: -77.4K Q2 '24: -19.7K Q3 '24: -26.7K Q4 '24: -34.9K Q1 '25: -11K Q2 '25: -13.6K Q3 '25: -15.5K Q4 '25: -14.7K Q1 '26: -11.4K Q2 '26: -10.2K Q3 '26: -4.6K Q4 '26: -2.7K Q1 '27: 4.2K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 10.9M Q1 '21: 10.9M Q2 '21: 52.4M Q3 '21: 54.5M Q1 '22: 205.4M Q2 '22: 205.5M Q3 '22: 205.5M Q1 '23: 206.5M Q2 '23: 206.5M Q3 '23: 206.5M Q1 '24: 207M Q2 '24: 207M Q3 '24: 207M Q1 '25: 207M Q2 '25: 207M Q3 '25: 207M Q1 '26: 207M Q2 '26: 207M Q3 '26: 207M Q1 '27: 207M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.02 -0.01 -0.01 0.00 0.01 0.01 0.02 Q1 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q4 '23: -0.02 Q1 '24: -0.02 Q2 '24: -0.02 Q3 '24: -0.02 Q4 '24: -0.01 Q1 '25: -0.01 Q2 '25: -0.01 Q3 '25: -0.01 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q3 '26: 0.00 Q4 '26: 0.00 Q1 '27: 0.00 Q4 '20 Q3 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.